HAYWARD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Kosan Biosciences today announced that Robert G. Johnson, Jr., M.D., Ph.D., Chief Executive Officer, will present at the SG Cowen 26th Annual Health Care Conference in Boston at the Marriott Copley Place on Monday, March 6, 2006 at 1:30 p.m. Eastern Time.
Interested parties may access a live webcast of Dr. Johnson's presentation by visiting the Calendar of Events page under News and Events on Kosan's website at http://www.kosan.com .
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. If you are unable to participate during the live webcast, a recorded replay of the presentation will be available one hour after the presentation is completed for two weeks.
About Kosan
Kosan Biosciences is advancing two new classes of anticancer agents through clinical development. Kosan's Hsp90 (heat shock protein 90) inhibitor (KOS-953) is in Phase I and II clinical trials for multiple myeloma and Her2 positive breast cancer. In addition, intravenous and oral formulations of a second-generation Hsp90 inhibitor, KOS-1022, are currently in Phase I clinical trials. Kosan is also developing KOS-862 in Phase II clinical trials in breast cancer, and a follow-on epothilone analog, KOS-1584, is in Phase I clinical trials. The epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan has generated a pipeline of additional product candidates, including KOS-2187 for gastrointestinal motility. For additional information about Kosan Biosciences, please visit the company's website at www.kosan.com.
Kosan Biosciences IncorporatedCONTACT: Robert G. Johnson, Jr., M.D., Ph.D., Chief Executive Officer ofKosan Biosciences, +1-510-732-8400, ext. 5243, or johnson@kosan.com
Web site: http://www.kosan.com/
